Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-25 @ 4:07 AM
Ignite Modification Date: 2025-12-26 @ 3:03 AM
NCT ID: NCT04207320
Description: For this Phase I study, NCI grade 1-4 AEs were to start being collected for on-study research participants from the initiation of Hydroxyurea/Azathioprine. No subject reached this point of the protocol while on study before their withdrawal. Thus, no AEs occurred for any of the three participants.
Frequency Threshold: 0
Time Frame: 0 years
Study: NCT04207320
Study Brief: Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) for Patients With Severe Sickle Cell Disease
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Stage I Stage I will include eligible subjects between the ages of 10-25 years. αβ+ T-cell depletion with Miltenyi CliniMACS system: Haploidentical CD34+ megadose hematopoietic stem cell transplant in which cells are purified using the Miltenyi CliniMACS system designed for αβ+ T-cell receptor selection using immunomagnetic beads. 0 None 0 0 0 0 View
Stage II Stage II will include eligible subjects between the ages of 2-25 years. αβ+ T-cell depletion with Miltenyi CliniMACS system: Haploidentical CD34+ megadose hematopoietic stem cell transplant in which cells are purified using the Miltenyi CliniMACS system designed for αβ+ T-cell receptor selection using immunomagnetic beads. 0 None 0 0 0 0 View
Serious Events(If Any):
Other Events(If Any):